|
| 34463836 | An online Sexual Health and Rehabilitation eClinic (TrueNTH SHAReClinic) for prostate cancer patients: a feasibility study. | Support Care Cancer | 2022 |
| 35354846 | Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. | Sci Rep | 2022 |
| 32967771 | Prognostic features of Annexin A2 expression in prostate cancer. | Pathology | 2021 |
| 34003011 | Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. | J Urol | 2021 |
| 33575208 | Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers. | Front Oncol | 2021 |
| 34302010 | Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia. | Sci Rep | 2021 |
| 32154908 | Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. | Cancer | 2020 |
| 31910880 | Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer. | J Transl Med | 2020 |
| 32111923 | Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. | Prostate Cancer Prostatic Dis | 2020 |
| 31741711 | Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies <i>ERG</i> as the strongest independent predictor of recurrence. | Oncotarget | 2019 |
| 29679998 | Legends in Urology. | Canadian Journal of Urology | 2018 |
| 28753864 | Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. | Eur Urol Focus | 2018 |
| 28652121 | High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial. | J Urol | 2018 |
| 29037514 | Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. | Eur Urol | 2018 |
| 29712692 | Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth. | Cancer Res | 2018 |
| 29730201 | Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. | J Urol | 2018 |
| 28065537 | Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer. | | 2017 |
| 28607007 | Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells. | Mol Cancer Res | 2017 |
| 28191285 | Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. | Genes Cancer | 2016 |
| 26780387 | Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. | BJU Int | 2016 |
| 26844274 | A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. | EBioMedicine | 2015 |
| 25465337 | A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. | Eur Urol | 2015 |
| 25883222 | Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN. | Oncotarget | 2015 |
| 25407442 | A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. | BJU Int | 2015 |
| 25808739 | Prostate cancer marker panel with single cell sensitivity in urine. | Prostate | 2015 |
| 25889691 | Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. | J Transl Med | 2015 |
| 24694733 | Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer. | Epigenetics | 2014 |
| 25279185 | Predominance of ERG-negative high-grade prostate cancers in African American men. | Mol Clin Oncol | 2014 |
| 24115221 | Evaluation of ERG responsive proteome in prostate cancer. | Prostate | 2014 |
| 24296774 | Anterior tumors of the prostate: clinicopathological features and outcomes. | Prostate Cancer and Prostatic Diseases | 2014 |
| 25221645 | Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. | Genes Cancer | 2014 |
| 25170998 | ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity. | Monoclon Antib Immunodiagn Immunother | 2014 |
| 24929891 | Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. | Urologic Oncology: Seminars and Original Investigations | 2014 |
| 21872499 | Low risk prostate cancer in men â¿¥ 70 years old: to treat or not to treat. | Urologic Oncology: Seminars and Original Investigations | 2013 |
| 22608541 | Health-related quality of life for men with prostate cancer--an evaluation of outcomes 12-24 months after treatment. | Urologic Oncology: Seminars and Original Investigations | 2013 |
| 23901346 | Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India. | J Cancer | 2013 |
| 23892597 | Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. | Int J Mol Sci | 2013 |
| 22077694 | Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. | BJU Int | 2012 |
| 22529743 | The burden of prostate cancer in Asian nations. | Journal of Carcinogenesis | 2012 |
| 22331093 | Clinical potential of the ERG oncoprotein in prostate cancer. | Nature Reviews Urology | 2012 |
| 22950997 | Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. | Urology | 2012 |
| 22054921 | New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. | Urology | 2011 |
| 21397300 | Prostate cancer in men less than the age of 50: a comparison of race and outcomes. | Urology | 2011 |
| 21074211 | Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. | Journal of Urology | 2011 |
| 21178489 | ERG oncogene modulates prostaglandin signaling in prostate cancer cells. | Cancer Biol Ther | 2011 |
| 21091976 | Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. | BJU Int | 2011 |
| 21805813 | Colorectal, prostate, and skin cancer screening among Hispanic and White non-Hispanic men, 2000-2005. | J Natl Med Assoc | 2011 |
| 21961743 | Words of wisdom. Re: Antibody-based detection of ERG rearrangement-positive prostate cancer. | | 2011 |
| 22096650 | Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort. | Prostate Cancer | 2011 |
| 22129214 | Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. | BJU International | 2010 |